Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Preliminary Efficacy of CD19 With IL-7 Receptor Alpha Signaling Chimeric Antigen Receptor T Cell (CMD63) in Relapse and Refractory Pediatric B-cell Acute Lymphoblastic Leukemia

NCT07078929 is registered in ClinicalTrials.gov with Chulalongkorn University as lead sponsor.

NCT NCT07078929
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07078929 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Preliminary Efficacy of CD19 With IL-7 Receptor Alpha Signaling Chimeric Antigen Receptor T Cell (CMD63) in Relapse and Refractory Pediatric B-cell Acute Lymphoblastic Leukemia
Lead sponsor
Chulalongkorn University
Phase
Phase 1
Overall status
Recruiting
Start date
January 1, 2026
Completion date
September 1, 2028
Enrollment
16 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

refactory childhood acute lymphoblastic leukemia, relapse b acute lymphoblastic leukemia